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Abstract: Central nervous system (CNS) myelin has a crucial role in accelerating the propagation
of action potentials and providing trophic support to the axons. Defective myelination and lack
of myelin regeneration following demyelination can both lead to axonal pathology and neurode-
generation. Energy deficit has been evoked as an important contributor to various CNS disorders,
including multiple sclerosis (MS). Thus, dysregulation of energy homeostasis in oligodendroglia may
be an important contributor to myelin dysfunction and lack of repair observed in the disease. This
article will focus on energy metabolism pathways in oligodendroglial cells and highlight differences
dependent on the maturation stage of the cell. In addition, it will emphasize that the use of alternative
energy sources by oligodendroglia may be required to save glucose for functions that cannot be
fulfilled by other metabolites, thus ensuring sufficient energy input for both myelin synthesis and
trophic support to the axons. Finally, it will point out that neuropathological findings in a subtype of
MS lesions likely reflect defective oligodendroglial energy homeostasis in the disease.
Keywords: energy metabolism; oligodendrocyte; oligodendrocyte progenitor cell; myelin; remyeli-
nation; multiple sclerosis; glucose; ketone bodies; lactate; N-acetyl aspartate
1. Introduction
Myelination is the key evolutionary event in the development of higher vertebrates.
This process significantly accelerates the propagation of action potentials without increasing
axonal diameter [1]. In addition, myelin has a neurotrophic role both in the central nervous
system (CNS) and the peripheral nervous system (PNS) [2]. Importantly, both myelin loss
and alterations in the composition of myelin compromise axonal health and can lead to
neurodegeneration [3–5].
Myelin is a multilamellar sheath that consists of water and dry weight. The dry weight
consists predominantly of lipids (70–80%) and, to a lesser extent, proteins (20–30%) [6].
In the CNS, myelin is produced by oligodendrocytes. Unlike Schwann cells, the
myelinating cells of the PNS, oligodendrocytes produce up to 50–80 internodes on multiple
axons (reviewed in [7]), which means that alterations in a small number of these cells
affect a significant number of axons. Importantly, alterations of oligodendrocytes and
CNS myelin are a feature of several CNS pathologies including leukodystrophies (genetic
disorders that lead to dys/de-myelination), spinal cord injury (in which myelin loss around
spared axons significantly contributes to permanent damage), multiple sclerosis (MS; a
chronic inflammatory demyelinating disease that leads to neurodegeneration) and other
inflammatory demyelinating CNS disorders, periventricular leukomalacia (white matter
disease of the newborn), as well as several “classical” neurodegenerative disorders such as
Alzheimer’s disease, etc. [8,9]. Designing treatments for some of these diseases should nec-
essarily involve therapies to preserve/regenerate myelin. To this end, it appears crucial to
understand the mechanisms governing myelin generation, maintenance, and regeneration.
Oligodendrocytes are generated by differentiation of oligodendrocyte progenitor cells
(OPCs) that themselves originate from defined germinal niches in the embryonic brain and
spinal cord [10]. OPCs colonize CNS parenchyma in successive waves [11]. A proportion
of these cells myelinates the axons, while another subset remains undifferentiated and
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constitutes the population of adult OPCs (aOPCs or so-called NG2 cells) [12]. Adult
OPCs represent 4–5% of the total CNS cells. In general, aOPCs proliferate at a low rate,
and differentiate and contribute to myelin turnover throughout adult life [13,14]. These
processes underlie the functional plasticity of the CNS in response to motor learning, for
example [14].
One of the most studied functions of aOPCs is myelin regeneration following de-
myelinating insults. Using animal models of demyelination, it has been shown that, upon
myelin loss, aOPCs undergo transcriptional changes that induce transition into so-called
“activated” state, and their proliferation rate increases. These cells migrate towards demyeli-
nated axons in response to defined cues, where they differentiate into oligodendrocytes and
regenerate myelin [12]. Interestingly, it has been shown that the process of (re)myelination
involves synaptic communication between axons and OPCs [15–17].
Therefore, a number of events are required for an OPC to successfully perform CNS
(re)myelination, namely: transcriptional activation of defined genes, proliferation in most
cases, migration towards axons to be (re)myelinated, synaptic communication with these
axons, differentiation into oligodendrocytes, and lipid and protein synthesis for myelin
(re)generation. These processes require energy (in the form of ATP) and building blocks for
lipids and proteins, which implies a tremendous investment of energy fuels and molecular
sources of carbon. In terms of energy, it has been estimated that OPCs generates three times
its own weight in membrane per day during myelination [18], which is likely to be similar
during myelin regeneration.
Once myelin is generated by an oligodendrocyte, it has to be maintained. It has been
estimated that oligodendrocytes maintain up to 100 times their own weight in membrane
throughout life [18]. Given that myelin maintenance is a dynamic process that involves
continuous lipid [19,20] and protein synthesis [21], oligodendrocytes are likely to require a
significant energetic/building block input throughout life. In addition, in the last decade,
it has been shown that oligodendrocytes provide axons with energy fuels [2], which adds
an additional energetic cost to the proper functioning of these cells.
Deciphering energetic demands and the sources of energy/building blocks used by
oligodendroglial cells (OPCs and mature oligodendrocytes) is, therefore, of major im-
portance for understanding myelin pathology in various CNS diseases and designing
treatments. Importantly, bioenergetic failure has been suggested as a cause of neurodegen-
eration in several CNS diseases, including Parkinson’s disease, Alzheimer’s disease, and
Huntington’s disease [22–25]. Regarding MS, several studies have highlighted impairments
in energy metabolism in active and inactive lesions, as well as in the normal-appearing
white matter in several cell types, including oligodendroglia [26–36]. Moreover, depletion
of ATP metabolites in the cerebrospinal fluid of MS patients is correlated with a more
severe disability progression [28]. Thus, it has been hypothesized that oligodendroglial
pathology/dysfunction and the development of permanent disability in MS result, at least
in part, from energy failure.
This review summarizes our current knowledge of energy metabolism pathways in
oligodendroglial cells, how these may differ during the process of differentiation, and
which energy sources might be crucial to sustain (re)myelination.
2. Oligodendroglial Functions Require Energy and Biosynthetic Precursors
The primary functions of oligodendroglia are myelination and trophic support to
the axons.
2.1. Energetic Cost of Myelin Synthesis
Myelination consists of biosynthetic reactions, namely lipid and protein synthesis,
which require input of simpler precursor molecules and consume energy.
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2.1.1. Lipid Synthesis
As mentioned above, lipids are the major component of myelin membranes (70–80% of
dry weight). The composition of myelin is unique as compared to other membranes, with
an approximate 2:2:1 ratio for cholesterol:phospholipids:glycolipids [37]. Myelin contains
80% of the cholesterol present in the brain. Blocking oligodendroglial cholesterol synthesis
in mice significantly delays myelination, even though this process eventually achieves
completion, thus suggesting that oligodendrocytes can obtain cholesterol by compensatory
mechanisms [38,39]. Indeed, it has been shown that myelination can be sustained in part
by astrocyte-derived lipids [40]. Unlike cholesterol, other lipids are built using fatty acids
as building blocks [20]. Blocking endogenous oligodendroglial fatty acid synthesis impairs
myelination and remyelination, which can be only partially rescued by dietary fatty acid
supplementation [41], thus highlighting the importance of oligodendroglial fatty acid
synthesis in myelination. Moreover, continuous lipid synthesis in oligodendrocytes is
required for myelin maintenance [19].
The first step of fatty acid synthesis is the synthesis of palmitate from acetyl CoA. This
process is fundamental in myelin generation, as the knockout of oligodendroglial fatty acid
synthase, the enzyme complex that carries out this process, impairs myelin generation and
repair [41]. The synthesis of one molecule of palmitate consumes 8 molecules of acetyl
CoA, 7 ATPs, and 14 NADPH, as well as 6 protons. In addition, as estimated by Harris and
Attwell [42], if one takes into account the loss of ATP generation when acetyl CoA molecules
are diverted from oxidative phosphorylation (ATP generation) to palmitate synthesis and
glucose molecules are diverted to PPP from glycolysis (to generate NADPH required),
the synthesis of palmitate costs 228 ATP molecules. The synthesis of one molecule of
phosphatidylethanolamine (a phospholipid) would cost 542 ATPs (equivalent to oxidative
phosphorylation of 18 glucose molecules) and galactosyl cerebroside (a galactolipid, a
subtype of glycolipids) 535 ATP molecules. Given that cholesterol used in myelin cannot
be imported from the circulation as it cannot cross the blood–brain barrier [43], it has to
be synthesized. The energetic cost for its synthesis would be of 306 ATPs per molecule.
Taking into account the normal lipid composition of myelin, the lipid production required
for one gram of myelin was estimated to cost 3.24 × 1023 ATP molecules [42].
2.1.2. Protein Synthesis
Myelin contains a defined set of proteins, the most abundant ones in the CNS being
myelin basic protein (MBP) and the proteolipid protein (PLP/DM20). The mechanism
underlying the synthesis of PLP is quite different from that of MBP synthesis. PLP is
synthesized at the rough endoplasmic reticulum, processed through the Golgi apparatus,
and transported via vesicles to the myelin membrane. However, in the case of MBP, mRNA
is transported along oligodendrocytes processes, and then translated locally at the axon-
oligodendrocyte contact site [44–46]. Thus, the energetic cost of the synthesis of CNS
myelin proteins includes the energy invested in peptide chain elongation, in addition to
the cost of mRNA transport along oligodendrocyte processes and local translation (in the
case of MBP), or that of vesicular transport (PLP).
Assuming that aminoacids were used only for protein synthesis and not as intermedi-
ates in the Kreb’s cycle, and that proteins represent 25% of myelin, Harris and Attwell [42]
calculated that the cost of protein production per gram of myelin should be of 6.84 × 1021
ATP molecules. This amount does not include the cost of protein targeting to the right
place within the myelin sheath.
Thus, in order to carry out lipid and protein synthesis, myelinating cells will require
a significant input of ATP, as described above, as well as extensive amounts of carbon
skeletons as building blocks.
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2.2. Oligodendroglial Trophic Support to the Axons Requieres Energy Investment and/or
Metabolite Shuttling
The notion that myelin may have functions other than that of insulator (for acceleration
of axonal conduction) arouse from the observations that mouse mutants for certain myelin
proteins show deficits in axonal transport and axonal degeneration in the absence of
demyelination [4,5]. This led to hypotheses that oligodendrocytes provide axons with
trophic support. Such possibility would explain how axons sustain their energy metabolism
given that they are spatially separated from the extracellular space by the myelin sheath,
except at the nodes of Ranvier.
Several modes of oligodendroglial trophic support to the axons have been described.
The first one, which has received much attention, is the so-called “oligodendrocyte-axon
lactate shuttle,” by which oligodendrocytes metabolize glucose to pyruvate through glycol-
ysis, convert pyruvate to lactate, and then export lactate via monocarboxylate transporter
1 (MCT1), expressed on myelin [47,48], to the axons [47] (Figure 1). An alternative expla-
nation for this lactate shuttling could be that oligodendrocytes may serve as a tunnel, by
importing lactate (through MCT1 that can both import and export lactate, or through gap
junctions from astrocytes) and shuttling it to the axons, rather than performing extensive
rounds of glycolysis (Figure 1).
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Figure 1. Metabolite shuttling between astrocytes, myelinating oligodendrocytes, and axons optimizes energy fuel use in the
central nervous system white matter. Glucose is imported into the parenchyma from the blood through Glut1 transporter on
endothelial cells, or directly into astrocytes through the same transporter. Astrocytes convert glucose to lactate and export
lactate to the extracellular space through MCT4. In addition, lactate as well as ketone bodies can also be imported from
the circulation into the parenchyma through MCT1 on endothelial cells. Oligodendrocytes can import glucose from the
extracellular space via Glut1 and lactate/ketone bodies via MCT1. Metabolites could also potentially enter oligodendrocytes
via connexin hemi hannels. In addit on, astrocytic lactate and glucose can be transferr d to oligode drocytes via gap
junctions formed by dime s of astrocytic conn xins 43 and 30 with olig dendrocyte connexins 47 and 32, resp ctively. In
order to provide axons with energy fuels, oligodendrocytes metabolize glucose to pyruvate through glycolysis, then convert
pyruvate to lactate, and export lactate to the periaxonal space via MCT1 expressed on myelin. Axons then import lactate via
MCT2. Oligodendrocytes may also export glucose to the periaxonal space via Glut1 that can then be uptaken by the axon
via Glut3. At the nodes of Ranvier, lactate is exported by astrocytes via MCT1 or MCT4 and imported by the axon via MCT2.
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The second mode of trophic support has been described by Meyer and colleagues, who
found that oligodendrocytes in the corpus callosum sustain compound action potentials by
delivering both glucose and lactate to the axons, and that pan-glial networks via connexin
47 are important in this process [49]. Moreover, thalamic oligodendrocytes have recently
been shown to assist astrocytes in delivering glucose and lactate to the axons to support
their synaptic activity [50]. The transport of metabolites from oligodendrocyte soma to
the axons likely involves networks of interconnected cytoplasmic pockets observed in the
myelin using high-pressure freezing electron microscopy [7].
Axonal trophic support by oligodendrocytes may also be carried out via myelin
peroxisomes, potentially by fatty acid transfer for beta oxidation in the axons [51]. Recently,
it has also been shown that oligodendrocytes support axonal transport and maintain the
health of nutrient-deprived axons in vitro via exosomes [52].
While the exact nature of oligodendroglial trophic support to the axons still remains to
be clarified, it is clear that the ability to provide nutrients to the axons will impose additional
energetic demands on oligodendroglia. The notion that oligodendrocytes supply axons
with lactate implies that these cells need to either produce lactate through glycolysis or
import it from the extracellular space and shuttle it to the axons. In order to provide the
axons with glucose, as shown by two reports [49,50], oligodendrocytes would have to
either import glucose (from the extracellular space or from astrocytes via gap junctions)
(Figure 1) and shuttle it to the axons, or produce glucose by gluconeogenesis. Yet, there is
no evidence that gluconeogenesis occurs in oligodendrocytes.
3. Energy Fuels Used by Oligodendroglia
As mentioned above, myelin synthesis and trophic support to the axons by mature
oligodendrocytes imply an extensive need for building blocks and ATP. Regarding differ-
entiating OPCs, energy fuels are required to sustain migration to demyelinated lesions,
proliferation, and myelin synthesis. While glucose is the main source of energy for all cells,
alternative fuels may also be important to sustain the energetic needs of oligodendroglia.
3.1. Glucose
3.1.1. Metabolizing Pathways
Glucose can be metabolized in the glycolytic pathway (which in the presence of oxygen
is in most cases followed by oxidative phosphorylation), pentose phosphate pathway, or
hexosamine pathway (Figure 2).
Glycolysis is the conversion of one molecule of glucose into two molecules of pyru-
vate, two hydrogen ions, and two molecules of water. This process consumes two
ATP molecules and generates four, resulting in the net gain of two ATP molecules per
one molecule of glucose, which means that it is not very efficient on its own in pro-
ducing energy. It also leads to production of two NADH molecules. Glycolysis is
not oxygen-dependent.
Oxidative phosphorylation: In the presence of oxygen, the pyruvate produced by
glycolysis is converted to acetyl Co-A, which is then oxidized in the Kreb’s cycle (tricar-
boxylic acid (TCA) cycle), to produce CO2, in addition to NADH and FADH2, the electron
carriers that pass the electrons to the electron transport chain. The reactions occurring in
the electron transport chain are denominated oxidative phosphorylation. This pathway is
the most efficient ATP-producing pathway (24–28 molecules per glucose molecule).
In the absence of oxygen, cells continuously undergo glycolysis in order to produce
ATP, and pyruvate is converted to lactate (or to ethanol in yeast). Lactate is then exported
from the cell. However, in some cases (for example, in cancer cells), cells preferentially
undergo glycolysis and export lactate even in the presence of oxygen. This phenomenon is
denominated the Warburg effect.
The pentose phosphate pathway (PPP) is a glucose-metabolizing biosynthetic path-
way that neither consumes nor produces ATP, and it does not require oxygen. The first
phase of this pathway is oxidative, and it converts NADP to NADPH, which will be used
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for (a) biosynthetic reactions as a reducing agent (e.g., fatty acid and sterol synthesis) and
(b) to prevent oxidative stress (production of glutathione and thioredoxin). The second
phase of PPP is a non-oxidative synthesis of 5-carbon sugar (riboses), used in the synthesis
of nucleotides and nucleic acids. Depending on the cellular needs, for example, if it needs
much more NADPH (fatty acid synthesis) than nucleotide production, after step 1 (oxida-
tive phase), the intermediates produced can enter the glycolytic pathway, resulting in the
production of pyruvate rather than continuing in the second phase.
The hexosamine pathway is a biosynthetic pathway that branches out of glycolysis
and converts fructose-6-phosphate into a key substrate for protein glycosylation, uri-
dine diphosphate N-acetyl glucosamine (UDP-GlcNAc). This pathway is crucial for the
biosynthesis of complex molecules such as glycoproteins, glycolipids, proteoglycans, and
glycosaminoglycans. It consumes approximately 2–5% of glucose that enters the cell. It
neither consumes nor produces ATP.




Figure 2. Schematic representation of metabolic pathways in oligodendroglial cells. Those indicated in red (glycolysis, 
pentose phosphate pathway, and hexosamine pathway) require glucose. The pathways circled in blue (fatty acid synthe-
sis, Kreb’s cycle, and oxidative phosphorylation ( electron transport chain)) can also be fueled by alternative sources of 
energy, namely lactate, ketone bodies, and N-acetyl aspartate (NAA). 
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3.1.2. Glucose Metabolism in Oligodendroglia: Vari tions across the Lineage
Glucose enters the cell through glucose transporters. In the brain, the expression of
facilitative diffusion glucose transporters GLUT1–6 and GLUT8 and the Na+-D-glucose
cotransporter SGLT1 has been demonstrated [53]. While gene expression data suggest
that OPCs may express Glut3, a high affinity transporter also expressed in neurons [54],
protein expression pattern of Glut expression on OPCs remains to be investigated. Oligo-
dendrocytes have been reported to express Glut1 [55], a transporter with high affinity,
although somewhat lower than that of Glut3 [56,57] and potentially also Glut2 [58,59]. In
addition, the expression of Glut1 by matur oligodendrocytes in vitro was increased f llow-
ing stimulation with glutama e NMDA rec ptor agonists [55], th refore highlighti g t at
axonal electrical activity, a fundamental inducer of myelination [60], increases metab lic
activity of oligodendrocytes. Importantly, Glut1 expression in rat oligodendrocytes was
reduced upon incubati n of thes cells w th antibodies or cerebrospinal fluid (CSF) is lated
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from the patients suffering from anti-NMDA receptor encephalitis, suggesting reduced
oligodendroglial metabolic activity in the disease [61].
3.1.3. Glycolysis versus Mitochondrial Metabolism
Numerous studies have examined the main pathways elicited by glucose in oligo-
dendroglia, and the results reported are somewhat contradictory, mainly regarding the
extent of mitochondrial metabolism in mature oligodendrocytes. The experiments on
cells isolated from the developing brain showed that oligodendrocytes oxidize twice as
much glucose as astrocytes in the Kreb’s cycle, just slightly less than neurons [62,63], thus
implying high rates of mitochondrial metabolism. In contrast, an in vivo study [64] showed
that deletion of Cox10 in post-mitotic oligodendrocytes, which prevents these cells from
forming a stable mitochondrial complex IV, did not affect CNS myelination nor axonal
integrity, thus suggesting that mitochondrial activity was not required to maintain mature
oligodendrocyte viability nor myelination in vivo. It is interesting to note that studies of
neuronal responses to mitochondrial mutations in vivo showed that Cox10 mutants had
prolonged survival (10–12 months) and less reactive oxygen species damage as compared
to the mitochondrial complex III mutants [65]. This suggests that Cox10 deletion, at least in
neurons, may not have completely abolished mitochondrial activity. Moreover, it has been
argued that mitochondrial defect in oligodendrocytes may become compensated by intact
astrocytic mitochondria [66]. Thus, further studies should be performed to confirm whether
mitochondrial metabolism in myelinating oligodendrocytes indeed becomes dispensable
in vivo.
Interestingly, in vitro studies have shown that the rate of glycolysis versus oxidative
phosphorylation/mitochondrial metabolism depends on the differentiation stage of oligo-
dendroglial cells. Thus, inhibition of mitochondrial complex IV lead to more extensive
injury of MBP-expressing oligodendrocytes than OPCs (both derived from post-natal rat
brain) [67], suggesting more extensive complex IV activity in mature cells in vitro. The
treatment of human cells with rotenone (complex I inhibitor) did not affect the survival
of undifferentiated OPCs nor differentiated oligodendrocytes, but it compromised the
viability of differentiating oligodendroglia [68], suggesting that newly generated oligo-
dendrocytes/late OPCs are the most vulnerable to complex I inhibition. In a study using
Seahorse analyzer to evaluate glycolytic versus mitochondrial ATP production, Rao and
colleagues observed that, under optimal conditions, cultured OPCs and oligodendrocytes
derived from postnatal rat brain rely on oxidative phosphorylation for ATP synthesis,
while oligodendrocytes isolated from the adult rat brain preferentially use glycolysis [69],
which appears consistent with the lack of myelinating oligodendrocyte pathology following
Cox10 deletion in vivo [64]. Following glucose deprivation, adult rat oligodendrocytes re-
duced glycolysis and increased oxidative phosphorylation [69]. Using the same technique
(Seahorse analyzer), Antel group also found that both human OPCs and oligodendro-
cytes isolated from adult tissue use glycolysis to generate ATP under optimal conditions
in vitro [70]. Moreover, both rat and human OPCs had higher oxygen consumption com-
pared to oligodendrocytes, and human cells (OPCs and oligodendrocytes) showed less
ATP production than cells derived from post-natal rat brain [70]. When exposed to nutrient
deprivation, human oligodendrocytes decreased ATP production, which was not the case
with OPCs. Therefore, it appears that, at least in vitro, both rat and human oligoden-
droglia show differences in energy metabolism and metabolic adaptations to nutrient stress
according to the differentiation state and the age of the tissue the cells were derived from.
3.1.4. Pentose Phosphate Pathway
As mentioned above, glucose can also enter the PPP pathway. Amaral and colleagues
showed, using C13 tracing studies, that oligodendrocytes metabolize 10–15% of the glucose
in the PPP [63], which is comparable to astrocytic PPP activity. This rate of the PPP
pathway is lower than the one in cell cultures with increased proportion of undifferentiated
OPCs [71], reported to be two-fold higher than that in astrocytes and four-fold higher than
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in neurons (reviewed by Amaral and colleagues [72]). This would be consistent with the fact
that proliferation in cultures with less differentiated cells is higher, and therefore, requires
more nucleotides (the generation of which requires PPP). However, as indicated by Amaral
and colleagues in a comprehensive and highly informative review of glucose metabolism
in oligodendroglial cells [72], it is possible that PPP activity in mature oligodendrocytes
may be higher than what was estimated, because the contribution of glucose metabolized
in the PPP to the lipid metabolism was not examined. Importantly, it has been reported
that de novo fatty acid and cholesterol synthesis are closely related to the rate of PPP in
oligodendroglial cells in the developing brain [73].
3.1.5. Hexosamine Pathway
The hexosamine pathway is likely to play an important role in myelination. As
mentioned above, this biosynthetic pathway leads to the production of glycoproteins, gly-
colipids, proteoglycans, and glycosaminoglycans. Importantly, several protein components
of myelin are glycoproteins (such as myelin associated glycoprotein (MAG) and myelin
oligodendrocyte glycoprotein (MOG)), and glycolipids are a fundamental component of
myelin. Moreover, proteoglycans such as NG2 are important determinants of OPC migra-
tion [74]. Indeed, it has been reported that N-glycan branching of GlcNAc is important in
myelination and myelin repair [75].
4. Alternative Sources of Energy and Biosynthetic Precursors
As mentioned above, glycolysis, PPP, and hexosamine pathways are strictly fueled
by glucose. However, the pathways using acetyl CoA, such as Kreb’s cycle/oxidative
phosphorylation and lipid synthesis, can also be directly fueled by alternative sources
(Figure 2). These include monocarboxylates and N-acetyl-aspartate (NAA), and appear
particularly important during developmental myelination (Figure 3).
4.1. Monocarboxylates (Ketone Bodies and Lactate) and Their Transporters in Oligodendroglia
The most important alternative fuels for the brain appear to be monocarboxylates, a
family of molecules that includes pyruvate, lactate, and ketone bodies (acetoacetate and
β-hydroxybutyrate). It is known that some of these substrates are essential for sustaining
brain function in specific situations, so that ketone bodies are used as an alternative energy
source during starvation or lactation while lactate represents an ATP source during intense
physical activity and in the newborn brain early after delivery [76]. In the past few decades,
lactate has also emerged as an important determinant of constitutive neuronal function as
it has been described as a preferred energy substrate (over glucose) for neuronal oxidative
metabolism in vitro [77], and more recently, in vivo [78,79]. Even though the brain can
take up lactate from systemic circulation under specific circumstances described above,
constitutive neuronal function is mostly sustained by lactate originating from two glycolytic
intra-cerebral cellular sources. Thus, astrocytes, in response to synaptic activity, increase
glycolysis, convert pyruvate to lactate, and shuttle lactate to neurons [80]. As mentioned
above, oligodendrocytes have also been shown to supply lactate to myelinated axons,
which appears crucial for neuronal activity and survival [50,81].
Monocarboxylate trafficking into/out of the cell requires monocarboxylate trans-
porters (MCTs) [82]. MCTs 1, 2, and 4 are expressed in the CNS, and they co-transport
monocarboxylates with a proton. MCT1 is the intermediate affinity transporter, which
means that it both imports and exports monocarboxylates. MCT2 is the highest affinity
transporter, and functions to import monocarboxylates into the cell. MCT4 is a high affinity
transporter, but it always exports lactate, even in high-lactate environments [76,83]). The
initial studies of MCT expression in the CNS demonstrated MCT1 as the most ubiquitously
expressed transporter, while MCT4 expression was described predominantly on astrocytes,
and that of MCT2 on neurons [82]. Regarding oligodendroglia, MCT1 expression has been
detected on myelin in vivo [48], which is important for lactate shuttling to the axons [47].
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The fact that oligodendrocytes express MCT1 suggests they can both import and ex-
port monocarboxylates. So far, this transporter has been mostly implicated in lactate export
to myelinated axons. Its expression was reported on oligodendrocytes but not OPCs in
one paper [47], but in another report, OPC upregulation of MCT1 was observed following
mild oxygen-glucose deprivation [84]. Viral-mediated deletion of MCT1 in myelinating
oligodendrocytes lead to axonal degeneration in absence of demyelination, suggesting
its predominant role in oligodendroglial trophic support to the axons [47]. Moreover,
decreased expression of this transporter in oligodendrocytes has been reported in human
brains during neurodegenerative diseases such as Creutzefeld Jacob [85], Alzheimer’s
disease [86,87], and Amyotrophic Lateral Sclerosis (ALS) [87]. A recent paper examined the
effects of conditional MCT1 deletion in oligodendroglial lineage and myelinating oligoden-
drocytes [88]. The results show that loss of MCT1 did not affect developmental myelination
or early axonal energy homeostasis. Evidence of axonal degeneration and hypomyelina-
tion was observed quite late, at 360 days of age, and was accompanied by an increase in
microglial reactivity. Only at 750 days of age did axonal degeneration become prominent.
Thus, the authors concluded that monocarboxylate metabolism is not an important deter-
minant of oligodendroglial energy metabolism, but that it becomes important with age,
when loss of MCT1 transporter on oligodendrocytes enhances age-induced degeneration.
It is important to mention that monocarboxylates (and other metabolites) could in theory
also be transferred via connexin channels from astrocytes to oligodendroglia [49,89,90]
(Figure 1) or through other MCTs. Importantly, connexin 30 (astrocytic form) and connexin
47 (oligodendrocyte form) double mutants exhibit hypomyelination [91]. Moreover, the
importance of pan-glial networks via connexin channels in oligodendroglial support of
axonal metabolism has been shown [49,50]. Thus, the absence of MCT1 in oligodendroglia
may have been compensated by monocarboxylate transport through connexin channels.
Moreover, in the recent years, studies of gene expression have suggested that the cells of
oligodendrocyte lineage may also express other MCTs [54], suggesting that these could
also participate in the oligodendroglial monocarboxylate metabolism.
4.1.1. Ketone Bodies as an Important Energy Fuel during Developmental Myelination
Experiments performed in 1970s–1980s showed that, in the developing brain, ketone
bodies appear to be an important substrate for myelin synthesis (Figure 3). Page, Krebs
and colleagues demonstrated that the blood levels of ketone bodies in the developing
rats exceeded 6–10 times those in adult animals, and that levels of enzymes involved in
ketone body utilization were three times higher in rats at weaning than in adult rats [92,93].
Importantly, ketone bodies were at least as important as glucose in terms of energy fuels [92].
This observation appears consistent with the fact that the developing brain may account for
up to 60% of the basal energetic demands of the body [94] as compared to 20% used by the
adult brain [95], which suggests increased energetic needs that may require additional fuels
to complement energetic inputs by glucose. Interestingly, administration of radioactively
labeled glucose versus ketone bodies to young rats (18–21 days old) showed that C14
incorporation into sterols and fatty acids in myelin (and in subcellular fractions) occurred
to a higher extent following ketone body as compared to glucose administration, thus
suggesting that ketone bodies are the preferential source of acetyl coA used for myelin
lipid synthesis [96]. While in this report, acetoacetate and D-3-hydroxybutyrate were used
to a similar extent during lipid synthesis, experiments performed on newborn rats showed
a preferential incorporation of β-hydroxybutyrate [97].
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Experiments in cell culture also showed incorporation of ketone bodies into lipids by
oligodendrocytes [100]. In addition, oligodendrocytes (as well as neurons and astrocytes)
isolated from the developing brain used ketone bodies to a 7–9 times greater extent than
glucose for oxidative metabolism, thus indicating that these cells may spare glucose for
pathways that cannot be fulfilled by fat metabolites [62] (Figure 2). A separate study
also reported that oligodendroglial oxidative metabolism and fatty acid and cholesterol
synthesis rely predominantly on ketone bodies and pyruvate, while glucose is rapidly
converted to lactate [101].
Levels of ketone bodies in the blood can be raised by administration of a ketogenic
(low-carbohydrate) diet [102]. Beneficial effects of a ketogenic diet on myelination have
been shown in a mouse model of Pelizaeus-Merzbacher disease (a fatal and incurable
leukodystrophy) with preserved blood–brain barrier [103]. In this model, a ketogenic diet
restored oligodendrocyte integrity and myelination, and reduced axonal degeneration.
Moreover, benefits of ketogenic diet were also reported in a patient with AGC1 deficiency,
the disease characterized by secondary hypomyelination due to a lack of N-acetylaspartate
(NAA) and defective oligodendroglial fatty acid metabolism. Administration of a ketogenic
diet to this patient led to a remarkable increase in myelination [104]. A ketogenic diet can
influence not only oligodendrocyte integrity, myelination, and axonal survival, but also
the inflammatory cell profile in the blood [105,106]. Slight improvements were observed in
clinical trials testing the effect of ketogenic diet in patients with MS, including a reduction
in inflammatory markers and a slight reduction in clinical scores in some cases [106].
4.1.2. Lactate Metabolism in Oligodendroglia: Differentiation State Matters?
Lactate is another potential alternative energy fuel for oligodendrocyte lineage cells.
Rinholm and colleagues reported that lactate rescues myelination in cerebellar slices when
these are exposed to glucose deprivation [48]. It is not completely clear whether in these
experiments lactate stimulated oligodendrocyte differentiation and myelination directly,
by providing oligodendroglial cells with energy or carbon skeletons for myelin synthesis,
or indirectly, by sustaining axonal activity which stimulated myelination. However, by pH
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imaging (lactate transport is coupled to that of a proton), the authors observed that the
main lactate importers were oligodendrocytes, suggesting that the stimulation of myelina-
tion was at least in part due to oligodendroglial import of lactate. Abarca and colleagues
also showed that lactate was utilized by oligodendrocytes in vitro as energy fuel and a
lipid precursor [71]. These authors administered C14-labeled lactate to oligodendroglial,
astrocytic, and neuronal cell cultures and observed a six-fold higher incorporation of C14
into lipids by oligodendrocytes as compared to neurons and type-2 astrocytes. Ichihara
and colleagues showed that lactate was able to rescue OPC cycling and differentiation
under low glucose conditions, which was inhibited by a lactate transporter inhibitor, α-
cyano-4-hydroxy-cinnamate [98]. The identity of the lactate transporter responsible for
lactate import into oligodendroglia was not investigated in these experiments. On the
other hand, Lee and colleagues showed that in vivo, oligodendrocytes export lactate to
the axons as a trophic support [47]. The apparently contradictory findings between the
reports in vitro/ex vivo claiming lactate utilization by oligodendroglia [48,71] and those
in vivo showing lactate export by glycolytic oligodendrocytes [47,64] could be interpreted
as a change in the metabolism of oligodendrocytes induced by myelination. However, it
could also be that the availability of lactate allows oligodendrocytes to sustain oxidative
phosphorylation and lipid synthesis, and thus, use glucose preferentially for lactate pro-
duction (and delivery to the axons), pentose phosphate pathway, and hexosamine pathway
(Figure 2). Accordingly, the paper by Amaral and colleagues showed that differentiated
oligodendrocytes incorporate C13-labeled lactate, and that the presence of this alternative
fuel stimulates glucose utilization via glycolysis, and consequently, lactate production [63].
Such compartmentalization of energy metabolism that spares glucose for functions that
can solely be fulfilled by this sugar (Figure 2) has also been suggested in the case of ketone
bodies [101]. Thus, it is possible that myelinating oligodendrocytes both use lactate for
lipid synthesis and produce lactate through glycolysis (Figures 1 and 2).
It should be kept in mind that lactate can function not only as a metabolite, but also
as a signaling molecule [107]. Lactate receptor, a G-Protein-Coupled Receptor 81/Hy-
droxycarboxylic Acid Receptor 1, is expressed in the brain [108]. While no reports so far
have described GPR81/HDAC1 expression specifically on oligodendroglia, the possibility
that lactate may affect oligodendroglial physiology as a signaling molecule rather than
as a metabolite cannot be excluded. It is, therefore, important to distinguish, as much
as possible, between the role of lactate as a signaling molecule versus that of an energy
fuel, which is possible experimentally by comparing the effect of L-lactate versus D-lactate
(a non-metabolizing molecule), and by performing experiments using lactate transporter
inhibitors, which inhibit lactate import/export but not signaling.
4.2. N-Acetyl-Aspartate Sustains Developmental Myelination
Acetyl CoA used by oligodendrocytes for lipid synthesis and/or ATP production can
be derived from glucose and monocarboxylates, but also from N-acetylaspartate (NAA)
(Figure 2). NAA is produced by neurons, and aspartoacetylase (ASPA), the enzyme that
catabolyzes NAA into L-aspartate and acetate, is expressed by oligodendrocytes [109]. The
transfer of NAA from the axons to oligodendrocytes represents an important metabolic
support for oligodendrocytes during myelination [110,111]. Loss of ASPA in oligodendro-
cytes renders these cells incapable of converting NAA to acetate, which leads to failure
of lipid synthesis and myelination observed in a leukodystrophy called Canavan’s dis-
ease [112]. Studies in ASPA-deficient tremor rat showed that deficient NAA metabolism
leads predominantly to myelin lipid abnormalities, indicating that NAA is an important
substrate for myelin lipid synthesis in the developing brain [113]. Moreover, studies of
ASPA-deficient mice show a decrease in myelin-associated lipids during postnatal myeli-
nation [112]. An in vitro study also suggested that aspartate derived from NAA is used
predominantly for lipid synthesis [114]. Yet, studies in a mouse model of Canavan´s
disease showed that ASPA loss affects both lipid synthesis and ATP production, thus
suggesting that NAA represents both a lipid precursor and fuel for ATP synthesis, which
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appears particularly important during developmental myelination [115]. Lastly, ASPA
deletion specifically in oligodendrocyte lineage in vivo resulted into hypomyelination, and
decreased galactosylceramide amounts in brain homogenates [116].
Thus, axons provide a significant metabolic support for oligodendrocytes via NAA
during developmental myelination (Figure 3). It remains to be determined whether this
mode of metabolic communication plays a role in myelin maintenance and/or remyelina-
tion.
5. Energetic Support of Remyelination?
Remyelination is a process by which lost myelin sheaths are regenerated around the
axons that have undergone demyelination. This process is highly efficient in young labora-
tory animals, but its rate slows down with age [117,118]. Remyelination is neuroprotective
in animal models and patients suffering from MS [3,119,120], which is why designing
strategies to stimulate this process appears crucial to prevent/diminish the development
of permanent neurological handicap associated with chronic MS.
Very little is known about metabolic requirements of CNS remyelination (Figure 3). A
recent paper suggested that microglial synthesis of desmosterol, a cholesterol precursor,
was required to support remyelination in mice subjected to cuprizone intoxication by
stimulating lipid recycling for myelin synthesis [99]. This paper also suggested that OPC
synthesis of cholesterol was not crucial for remyelination. Another paper suggested that
glycogen-derived lactate plays a role in remyelination in a cuprizone model [98]. However,
it was not clear whether this effect was mediated by lactate support of neuronal activity
(that stimulates myelination) or direct support to OPCs/differentiating oligodendrocytes.
Thus, deciphering the energetic mechanisms underlying the process of CNS remyelination
is a major challenge.
Importantly, the notion that the sole effectors of successful remyelination are OPCs has
been challenged. Thus, CNS demyelination in cats fed with irradiated diet and vitamin B12-
deficient monkeys occurred because oligodendrocytes stopped myelinating, even though
they did not die [121]. Importantly, remyelination in these models was carried out by
surviving mature oligodendrocytes [122]. These results have important implications for the
subtype of demyelinated MS lesions in which mature oligodendrocytes are preserved [123],
as they indicate that oligodendrocytes that survive demyelination can participate in re-
myelination. It remains to be determined whether this type of demyelination may be a
consequence of dysregulated energy homeostasis in the CNS. Notably, it has been shown
that acute MS lesions are hypermetabolic [124], which suggests that ongoing inflammatory
activity may consume local energy sources, and thus, potentially compromise the energetic
support for (re)myelinating cells.
6. Distinct Differentiation Stage-Specific Responses of Oligodendroglia to Nutrient
Deprivation: Relevance to Demyelinating Pathology
Several studies have examined the responses of oligodendroglial cells to metabolic
stress. Exposure of rodent oligodendroglia to glucose deprivation induced extensive
changes in the processes of OPCs but not in those of mature oligodendrocytes [84]. An-
other study showed that under low glucose conditions in vitro OPC survival, proliferation,
and differentiation were decreased but could be rescued by lactate supplementation [98].
Studies using human oligodendroglia showed that exposure of OPCs and oligodendro-
cytes to low glucose conditions initially leads to marginal cell death accompanied by
extensive process retraction by oligodendrocytes, which was associated with a decrease in
the rate of glycolytic metabolism [70]. Significant apoptosis in this report was observed
only after 6 days of glucose deprivation. A more recent study showed that the age of the
tissue the human cells were derived from determines the susceptibility of oligodendroglial
cells to nutrient-induced apoptosis. Thus, fetal-derived human oligodendroglia were the
most susceptible to apoptosis after nutrient deprivation, and pediatric cells were more
susceptible than adult-derived oligodendrocytes [125]. The survival of adult human tissue-
derived oligodendrocytes upon nutrient deprivation was related to an upregulation of
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anti-apoptotic Bcl-2 family. Moreover, under these conditions, adult human oligodendro-
cytes upregulated autophagy (a process that can mobilize cellular energy stores [126]),
which maintained their survival in the short term. Long-term exposure of adult human
oligodendrocytes to nutrient deprivation led to cell death that was different from apopto-
sis [125]. Importantly, the main response of adult oligodendrocytes to nutrient deprivation
was process retraction and low metabolic rate, which compromised myelination, but pre-
served survival [70]. This in vitro phenomenon has been associated with distal process
retraction by oligodendrocytes, previously described as dying-back oligodendropathy [127],
and demyelination observed in a subtype of MS lesions [121]. This pathology appears
reversible until a specific point of no return is reached [121], suggesting that oligodendro-
cytes that stop myelinating in response to metabolic stress may recover their myelinating
function if optimal conditions are restored. Interestingly, exposure of cats to irradiated
diet led to demyelination, and the return to normal diet was followed by remyelination by
pre-existing oligodendrocytes [122,128]. Thus, it may be that the initial response of myeli-
nating oligodendrocytes to metabolic stress is to retract processes and stop myelinating in
order to save the energy for survival. Such lack of myelination may be reversible if nutrient
deprivation does not extend in time. However, long-term deprivation leads to mature
oligodendrocyte death that is different from apoptosis (Figure 4). Interestingly, a study
of aging in the female brain reported that white matter lipids may be used as a source of
energy [129], thus suggesting that energy-deprived oligodendrocytes might even oxidize
myelin fat to obtain energy for survival. Such observations have important implications for
strategies to prevent myelin loss/stimulate myelin repair in multiple sclerosis, and should
be addressed by future studies.
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Oligodendrocytes and their progenitors require a significant input of carbon sources 
and energy fuels to sustain myelin synthesis and ATP production. Moreover, myelinat-
ing oligodendrocytes also invest energy to provide trophic support to the axons. It is 
likely that, in addition to glucose, complementary energy fuels might be required to ful-
fill oligodendroglial energetic needs and assure correct myelination and axonal support. 
Unravelling the mechanisms underlying oligodendroglial energy metabolism should in-
crease our understanding of oligodendroglial pathology in demyelinating diseases, and 
thus, provide novel clues for therapies that aim to prevent myelin loss/enhance myelin 
regeneration. 
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